(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis

Official Title

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy

Summary:

This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis (SSM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.

Trial Description

Primary Outcome:

  • Recommended Phase 2 dose (RP2D) in patients with ISM (Part 1)
  • Mean change in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS) in patients with ISM and SSM (Part 2)
  • Mean change in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS) in patients with ISM and SSM (long term, Part 3)
  • Safety of avapritinib as assessed by number of adverse events (long term, Part 3)
Secondary Outcome:
  • Change in serum tryptase
  • Change in V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog aspartate 816 valine (KIT D816V) allele burden in blood
  • Change in bone marrow mast cells
  • Change in skin mast cells in patients with baseline cutaneous mastocytosis (CM)
  • Change in percent body surface area (BSA) involved by CM
  • Change in pigmentation of cutaneous lesions in patients with baseline CM as assessed by skin photography
  • Change in best supportive care (BSC) concomitant medication usage
  • Change in Mastocytosis Quality of Life Questionnaire (MC-QoL)
  • Change in Patient's Global Impression of Symptom Severity (PGIS)
  • Change in 12-item Short Form Health Survey (SF-12)
  • Change in Patients' Global Impression of Change (PGIC)
  • Change in EuroQuol 5 Dimensions 5 Levels (EQ 5D-5L)
  • Safety of avapritinib as assessed by number of adverse events
  • Area Under Curve (0 to Tau) for avapritinib (Parts 1 and 2 only)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society